Protective effects of naringin against oxidative stress, inflammation, apoptosis, and DNA damage in rats with doxorubicin-induced hepatotoxicity
Pelin Durukan Azman , Serkan Yildirim , Emin Sengul , Mohamad Warda , Samet Tekin , Furkan Aykurt , Ali Cinar
Asian Pacific Journal of Tropical Biomedicine ›› 2025, Vol. 15 ›› Issue (7) : 285 -295.
Protective effects of naringin against oxidative stress, inflammation, apoptosis, and DNA damage in rats with doxorubicin-induced hepatotoxicity
Objective: To investigate the protective effects of naringin on doxorubicin (DOX)-induced liver injury.
Methods: A total of 50 male rats were allocated into five groups: the control group, the DOX group, the DOX groups treated with 50 mg/kg and 100 mg/kg of naringin by gastric lavage for 10 days, as well as the group treated with 100 mg/kg of naringin alone. Liver and serum samples were collected for biochemical, histopathological, and molecular analyses, including liver enzyme activity, oxidative stress markers, inflammation, apoptosis-related proteins, and DNA damage indicators.
Results: Naringin attenuated DOX-induced elevation in liver enzyme activity and inflammation markers while enhancing antioxidant activities. Naringin also activated the Nrf2-HO-1 signaling pathway, with the most pronounced effect in the high-dose naringin group. In addition, naringin modulated apoptotic signaling by downregulating the expression of PI3K-AKT and BAX, and upregulating Bcl-2, as well as reduced the level of 8-OHdG. Histopathological evaluation showed that DOX-induced structural liver alterations, such as cellular degeneration and necrosis, were notably attenuated by naringin treatment.
Conclusions: Naringin treatment exerts protective effects against DOX-induced liver injury through its antioxidative, anti-inflammatory, and anti-apoptotic effects.
Doxorubicin / Hepatotoxicity / Inflammation / Naringin / Oxidative stress
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
/
| 〈 |
|
〉 |